WILLOW BIOSCIENCES INC - CANSF STOCK NEWS

Willow Biosciences Inc. announced a collaboration with a leading Active Pharmaceutical Ingredient (API) manufacturer to develop a more sustainable, cost-effective manufacturing route for their largest product sold globally. The partnership program will focus on optimizing an existing commercial biomanufacturing process for improved performance at scale. The development phase of this funded collaboration is expected to last approximately six months with additional milestone payments for achieving defined performance targets. Willow's President & CEO, Dr. Chris Savile, expressed excitement about the potential impact on human health and the value to the partner and shareholders. This agreement represents the second new development agreement executed by Willow in only the first few weeks of 2024, with a robust pipeline of other potential collaborations in process.

Willow Biosciences Inc. announced a collaboration with Enterin, Inc. to develop sustainable manufacturing routes for key intermediates and active pharmaceutical ingredients. The collaboration is expected to last approximately three months and represents the 3rd development agreement with companies seeking access to Willow's transformative BioOxiTM selective hydroxylation platform.

Willow Biosciences Inc. (TSX: WLLW) (OTCQB: CANSF) achieved record revenues of approximately $1.3 million in 2023, representing a 60% increase from the previous year. The company launched the BioOxi bio-oxidation platform technology, strengthened its portfolio of partnered and proprietary programs, and underwent successful corporate and operational reorganization. In 2024, Willow anticipates significant revenue growth, execution of commercial agreements, and the closing of new partnership agreements.

Willow Biosciences Inc. (WLLW) announces a program with a Nasdaq-listed biopharma company to develop manufacturing routes to advanced intermediates and high-value active pharmaceutical ingredients. The program is expected to bring immediate R&D revenue and first commercial supply revenue as early as 2024, validating Willow's BioOxi™ technology and strategic focus on near-term revenue generation.

Willow Biosciences Inc. (WLLW) reports record revenues for the third quarter and the nine months ended September 30, 2023. They also filed a patent application for a process to produce corticosteroids at a significant cost reduction and signed two new program agreements, advancing three programs to the next phase of development. The company's financial and operating results show significant progress in sustainable business growth and commercial expansion.

Willow Biosciences completes convertible debenture offering for C$800,000

Willow Biosciences and SUANFARMA collaborate on a cell line productivity optimization program for manufacturing anti-infective API through precision fermentation. SUANFARMA will use Willow's strain optimization technologies to develop a more cost-effective production process. The partnership aims to create alternative means for sustainable production. This collaboration marks progress in broadening the relationship and expanding the joint product portfolio. Willow develops and produces precision fermented functional ingredients for various markets. SUANFARMA is a B2B life science partner specialized in the development, production, and commercialization of ingredients. No specific financial figures or percentages are mentioned in the PR.

Willow Biosciences Inc. has successfully completed research and development on its program to produce ursodeoxycholic acid (UDCA), a large volume active pharmaceutical ingredient (API) used in nutraceutical and pharmaceutical products. This breakthrough was made possible by Willow's BioOxi technology, which solves for selective C-H hydroxylation at industrial scale. Willow anticipates receiving milestone payments and revenue upon commercialization by Sandhill.

Willow Biosciences announces development of a cost-reducing process for corticosteroids manufacturing using BioOxi platform